The German method for setting ceiling prices for drugs: in some cases less data are required.

Abstract:

:The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased future health expenditures from prolonging life (i.e., downstream costs). This article suggests that because of the specific requirements of the Institute for Quality and Efficiency in Health Care, in some cases calculation of downstream costs is not necessary when clinical outcomes are used as a measure of effectiveness. In this article, we identify these conditions. If they hold, it will reduce data requirements, the costs and time required to conduct evaluations, and the uncertainty in the analysis.

authors

Gandjour A,Gafni A

doi

10.1586/erp.11.45

subject

Has Abstract

pub_date

2011-08-01 00:00:00

pages

403-9

issue

4

eissn

1473-7167

issn

1744-8379

journal_volume

11

pub_type

杂志文章
  • Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

    abstract:BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1476142

    authors: Grewal S,Ramsey S,Balu S,Carlson JJ

    更新日期:2018-08-01 00:00:00

  • Risk selection in a regulated health insurance market: a review of the concept, possibilities and effects.

    abstract::The Dutch basic health insurance is based on the principles of regulated competition. This implies that insurers and providers compete on price and quality while the regulator sets certain rules to achieve public objectives such as solidarity. Two regulatory aspects of this scheme are that insurers are not allowed to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2013.841546

    authors: van Kleef RC,van de Ven WP,van Vliet RC

    更新日期:2013-12-01 00:00:00

  • Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.

    abstract:BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2019.1632194

    authors: Wijnen BFM,Thielen FW,Konings S,Feenstra T,Van Der Gaag M,Veling W,De Haan L,Ising H,Hiligsmann M,Evers SMAA,Smit F,Lokkerbol J

    更新日期:2020-06-01 00:00:00

  • The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.

    abstract::The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1080/14737167.2017.1385394

    authors: Novakovic T,Martin AP,Parker M,Ferrario A,Vukovic S,Łanda K,Duba J,Dankó D,Kotsopoulos N,Godman B,Ristic J,Stefanovic D,Tesic D

    更新日期:2017-12-01 00:00:00

  • Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.

    abstract:OBJECTIVE:To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. RESEARCH DESIGN AND METHODS:Two independent contributors reviewed the statements of the TC, recommendations iss...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1384696

    authors: Kawalec P,Malinowski KP,Trąbka W

    更新日期:2018-04-01 00:00:00

  • Metastatic melanoma in the older patient: immunologic insights and treatment outcomes.

    abstract::Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.14

    authors: Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

    更新日期:2011-04-01 00:00:00

  • Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

    abstract:INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2019.1554437

    authors: Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

    更新日期:2019-04-01 00:00:00

  • Management and costs of severe psoriasis: the role of new biologics.

    abstract::It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.5.573

    authors: Feldman SR,Pearce DJ

    更新日期:2004-10-01 00:00:00

  • Radiotherapy cost-calculation and its impact on capacity planning.

    abstract::The rapid rise in health care expenses has resulted in an increased interest in the cost of treatments from a cost-effectiveness point of view for management purposes and in a reimbursement setting. The economics of radiotherapy within the global context of health care, and more specifically of cancer therapy, are dis...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.4.497

    authors: Lievens Y,Slotman BJ

    更新日期:2003-08-01 00:00:00

  • Toward new legislation on drugs in Europe.

    abstract::Everybody acknowledges the merits of the European Medicines Evaluation Agency and the progress the European system has permitted in evaluating and approving medicinal products. Nevertheless, the system established in 1995 is ripe for updating and improvement in the light of experience. Some limitations of the procedur...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2.1.51

    authors: Garattini S,Bertele' V

    更新日期:2002-02-01 00:00:00

  • Applying a developmental approach to quality of life assessment in children and adolescents with psychological disorders: challenges and guidelines.

    abstract::Research on the quality of life (QL) of children/adolescents with psychological disorders has flourished over the last few decades. Given the developmental challenges of QL measurements in pediatric populations, the aim of this study was to ascertain the extent to which a developmental approach to QL assessment has be...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2015.972377

    authors: Carona C,Silva N,Moreira H

    更新日期:2015-02-01 00:00:00

  • Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples.

    abstract:OBJECTIVE:This systematic review and meta-analysis aimed to reassess the effectiveness of condoms in reducing heterosexual transmission of HIV. METHODS:Medline, Scopus, and the ISI Web of Science databases were searched up to June 2014. Eligible studies were synthesized using random-effects models. RESULTS:Twenty-fiv...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737167.2016.1102635

    authors: Giannou FK,Tsiara CG,Nikolopoulos GK,Talias M,Benetou V,Kantzanou M,Bonovas S,Hatzakis A

    更新日期:2016-08-01 00:00:00

  • Antibiotics and reduced risk of COPD re-exacerbations.

    abstract::Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.33

    authors: Antoniu SA

    更新日期:2009-08-01 00:00:00

  • Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria.

    abstract:BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1375407

    authors: Feig C,Cheung KL,Hiligsmann M,Evers SMAA,Simon J,Mayer S

    更新日期:2018-04-01 00:00:00

  • Quality of life in cancer clinical trials: researchers, patients and policy makers.

    abstract::The second symposium of the European Organisation for Research and Treatment of Cancer took place in September 2011 at the European Parliament in Brussels (Belgium). The aim of the symposium was to discuss a wide range of topics in health-related quality of life, symptom research and cancer clinical trials, including ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1586/erp.11.84

    authors: Dormer L

    更新日期:2011-12-01 00:00:00

  • Prevalence, awareness, and burden of major depressive disorder in urban China.

    abstract:OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patie...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2016.1102062

    authors: Gupta S,Goren A,Dong P,Liu D

    更新日期:2016-06-01 00:00:00

  • Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.

    abstract::Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical tr...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.3.227

    authors: Wade WE,Spruill WJ

    更新日期:2007-06-01 00:00:00

  • The power of r - pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?

    abstract::The pharmaceutical sector has been established as the primary cost driver in health. The scope of this paper is to explore the drivers of pharmaceutical expenditure in Cyprus by decomposing sales and assessing impact of prices, volumes and substitution effect. We used a statistical approach to decompose the growth of ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2014.889565

    authors: Petrou P

    更新日期:2014-04-01 00:00:00

  • Quality of care of asthma during pregnancy.

    abstract::The goal of asthma management during pregnancy is to keep the mother symptom free and to prevent complications in the fetus. Asthma is a common chronic condition in pregnancy that, if inadequately treated, has the potential to cause adverse effects for both mother and fetus. Aggressive treatment during pregnancy can d...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.1.67

    authors: Streck MR,Blaiss MS

    更新日期:2006-02-01 00:00:00

  • The minimum clinically important difference for EQ-5D index: a critical review.

    abstract::The European Quality of Life-5 Dimensions Questionnaire (EQ-5D) is the most common instrument to value health outcomes under the patient's perspective. Several studies have investigated whether observed changes are meaningful to patients, using a variety of approaches to estimate the minimum clinically important diffe...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.894462

    authors: Coretti S,Ruggeri M,McNamee P

    更新日期:2014-04-01 00:00:00

  • Economic considerations and future directions for lung volume reduction surgery.

    abstract::Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.6.729

    authors: Reed A,Williams T,Snell G

    更新日期:2003-12-01 00:00:00

  • Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.

    abstract:OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2015.1065734

    authors: Hu S,Yu X,Chen S,Clay E,Toumi M,Milea D

    更新日期:2015-01-01 00:00:00

  • Short- and long-term HRQOL issues following brachytherapy for prostate cancer.

    abstract::Given the lack of evidence from randomized controlled trials and large prospective studies, controversy exists regarding the optimal treatment strategy for early stage prostate cancer. The impact of various treatments on health-related quality of life has become an increasingly important but controversial issue. The l...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.3.277

    authors: D'haese S,Bottomley A

    更新日期:2004-06-01 00:00:00

  • New management of the pregnant patient to reduce the risk of transmitting herpes to the newborn.

    abstract::Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.6.783

    authors: Baker DA

    更新日期:2005-12-01 00:00:00

  • The process of reconciliation: evaluation of guidelines for translating quality-of-life questionnaires.

    abstract::Reconciliation refers to the process through which two or more independent forward translations are merged into one single translation. This critical step in the translation process is difficult to formalize. The purpose of this review is to analyze how reconciliation is specified in leading guidelines for the transla...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.102

    authors: Koller M,Kantzer V,Mear I,Zarzar K,Martin M,Greimel E,Bottomley A,Arnott M,Kuliś D,ISOQOL TCA-SIG.

    更新日期:2012-04-01 00:00:00

  • Cost-effective approaches to influenza prevention and treatment.

    abstract::Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.2.141

    authors: Rothberg M

    更新日期:2005-04-01 00:00:00

  • How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.

    abstract::In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.859525

    authors: Diaby V,Goeree R

    更新日期:2014-02-01 00:00:00

  • Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.

    abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1800457

    authors: Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

    更新日期:2020-08-01 00:00:00

  • Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions.

    abstract::Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.12.24

    authors: Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

    更新日期:2012-06-01 00:00:00

  • A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis.

    abstract::The past 10 years has witnessed a major transformation in the treatment of rheumatoid arthritis, a chronic condition that leads to significant morbidity, impairment in quality of life and mortality. Adalimumab joins a class of biologic response modifiers that prevent joint destruction and maintain functional status. F...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.5.519

    authors: Bansback N,Brennan A,Anis AH

    更新日期:2005-10-01 00:00:00